Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Houston, TX
NPI: 1336249960Primary Practice Location
Medical Center Endoscopy
6560 Fannin Street, Houston, TX
Primary Employer
Luis H Camacho MD MPH PA
houstonmethodist.org
HQ Phone
Get M.D., MPH Luis's Phone Numberphone_androidMobile
Get M.D., MPH Luis's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTX State Medical License
TX State Medical License
2001 - 2027
American Board of Internal Medicine
Medical Oncology
Memorial Sloan Kettering Cancer Center
Fellowship • Hematology and Medical Oncology
1998 - 2001
George Washington University
MPH • Public Health - Administration
1996 - 1998
Residency • Internal Medicine
1995 - 1998
Military University Nueva Granada
Medical School
Until 1988
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 104 | 227 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 96 | 195 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 32 | 128 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 26 | 26 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 24 | 24 |
Current Status of Biosimilars in Oncology.
Authors: Luis Camacho
Publication Date: 2017-05-07
Pharmacodynamics of decitabine 5 days/week x 2 weeks in advanced cancers.
Authors: Yasuhiro Oki
Publication Date: 2005-06
Authors: David Perrault, Lawrence Cai, Gordon Lee, Connor Arquette
Journal: J Plast Reconstr Aesthet Surg
Publication Date: 2023-06-10
Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Intervention / Treatment: DRUG: Fuzuloparib , Abiraterone acetate and Prednisone, DRUG: Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Collaborators: Atridia Pty Ltd.
Intervention / Treatment: DRUG: SHR-A1811
Lead Sponsor: MacroGenics
Intervention / Treatment: BIOLOGICAL: enoblituzumab plus ipilimumab
